103 phenotypes from 7 alleles in 12 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Hmox1em1(IMPC)Mbp/Hmox1+ C57BL/6N-Hmox1em1(IMPC)Mbp/MbpMmucd	abnormal placenta morphology	J:211773
	edema	J:211773
	hemorrhage	J:211773
	microphthalmia	J:211773
Hmox1em1(IMPC)Mbp/Hmox1em1(IMPC)Mbp C57BL/6N-Hmox1em1(IMPC)Mbp/MbpMmucd	abnormal craniofacial morphology	J:211773
	abnormal facial morphology	J:211773
	abnormal head shape	J:211773
	abnormal placenta morphology	J:211773
	abnormal placenta size	J:211773
	embryonic growth retardation	J:211773
	preweaning lethality, complete penetrance	J:211773
	preweaning lethality, incomplete penetrance	J:211773
Hmox1tm1.1Gkl/Hmox1tm1.1Gkl Lyz2tm1(cre)Ifo/Lyz2+ involves: 129 * 129P2/OlaHsd * BALB/cJ * C57BL/6	decreased interferon-beta secretion	J:148498
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:148498
	decreased susceptibility to Paramyxoviridae infection	J:148498
	increased B cell number	J:148498
	increased CD4-positive, alpha-beta T cell number	J:148498
	increased CD8-positive, alpha-beta T cell number	J:148498
	increased circulating tumor necrosis factor level	J:148498
	increased granulocyte number	J:148498
	increased interferon-gamma secretion	J:148498
	increased macrophage cell number	J:148498
	increased splenocyte proliferation	J:148498
	increased susceptibility to experimental autoimmune encephalomyelitis	J:148498
Hmox1tm1.1Hes/Hmox1tm1.1Hes Lyz2tm1(cre)Ifo/Lyz2+ involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N	abnormal cellular respiration	J:214639
	abnormal metabolism	J:214639
	abnormal mitochondrial physiology	J:214639
	abnormal redox activity	J:214639
	decreased circulating free fatty acids level	J:214639
	decreased fat cell size	J:214639
	decreased inflammatory response	J:214639
	decreased interleukin-1 beta secretion	J:214639
	decreased interleukin-6 secretion	J:214639
	decreased susceptibility to diet-induced hepatic steatosis	J:214639
	decreased susceptibility to weight gain	J:214639
	decreased tumor necrosis factor secretion	J:214639
	improved glucose tolerance	J:214639
	increased energy expenditure	J:214639
	increased insulin sensitivity	J:214639
Hmox1tm1.1Hes/Hmox1tm1.1Hes Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA	abnormal cellular respiration	J:214639
	abnormal metabolism	J:214639
	abnormal mitochondrial physiology	J:214639
	abnormal redox activity	J:214639
	decreased circulating alanine transaminase level	J:214639
	decreased circulating aspartate transaminase level	J:214639
	decreased susceptibility to diet-induced hepatic steatosis	J:214639
	increased insulin sensitivity	J:214639
Hmox1tm1.1Hes/Hmox1tm1.1Hes Tg(Ckmm-cre)5Khn/0 involves: C57BL/6J * C57BL/6N * FVB/N	normal homeostasis/metabolism phenotype	J:214639
Hmox1tm1.1Hes/Hmox1tm1.1Hes Tg(Fabp4-cre)1Rev/0 involves: C57BL/6J * C57BL/6N	normal homeostasis/metabolism phenotype	J:214639
Hmox1tm1.1Hes/Hmox1tm1.1Hes Tg(Ins2-cre)25Mgn/0 involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA	normal homeostasis/metabolism phenotype	J:214639
Hmox1tm1.2Gkl/Hmox1tm1.2Gkl involves: 129 * BALB/cJ * C57BL/6	enlarged spleen	J:148498
	increased inflammatory response	J:148498
	liver inflammation	J:148498
	postnatal lethality, incomplete penetrance	J:148498
	premature death	J:148498
Hmox1tm1Mlee/Hmox1tm1Mlee B6.129S2-Hmox1tm1Mlee	abnormal artery morphology	J:106600
	abnormal vascular smooth muscle physiology	J:106600
	increased vascular smooth muscle cell proliferation	J:106600
Hmox1tm1Mlee/Hmox1tm1Mlee involves: 129S2/SvPas * BALB/c	abnormal response to cardiac infarction	J:54684
	abnormal thrombosis	J:54684
	cardiac fibrosis	J:54684
	cerebral edema	J:153083
	dilated heart right ventricle	J:54684
	increased cardiomyocyte apoptosis	J:54684
	increased circulating alanine transaminase level	J:153083
	increased heart right ventricle weight	J:54684
	increased susceptibility to parasitic infection	J:153083
	increased susceptibility to parasitic infection induced morbidity/mortality	J:153083
	liver failure	J:153083
	myocardium necrosis	J:54684
	oxidative stress	J:54684
	perinatal lethality, incomplete penetrance	J:54684
	postnatal lethality, incomplete penetrance	J:54684
Hmox1tm1Poss/Hmox1tm1Poss involves: 129 * 129S2/SvPas * C57BL/6J	anemia	J:282829
	decreased macrophage cell number	J:282829
	prenatal lethality, incomplete penetrance	J:282829
Hmox1tm1Poss/Hmox1tm1Poss involves: 129S2/SvPas * C57BL/6	abnormal iron homeostasis	J:79254
	abnormal leukocyte cell number	J:79254
	abnormal lymph node cell ratio	J:79254
	abnormal splenic cell ratio	J:79254
	anisocytosis	J:79254
	cachexia	J:79254
	chronic inflammation	J:79254
	decreased body size	J:79254
	decreased circulating iron level	J:79254
	decreased erythrocyte cell number	J:79254
	decreased hematocrit	J:79254
	decreased hemoglobin content	J:79254
	decreased locomotor activity	J:79254
	decreased mean corpuscular volume	J:79254
	enlarged lymph nodes	J:79254
	enlarged spleen	J:79254
	extramedullary hematopoiesis	J:79254
	glomerular crescent	J:79254
	glomerulonephritis	J:79254
	glomerulosclerosis	J:79254
	increased blood urea nitrogen level	J:62437
	increased circulating ferritin level	J:79254
	increased renal tubule apoptosis	J:62437
	infertility	J:79254
	kidney failure	J:62437
	liver fibrosis	J:79254
	liver inflammation	J:79254
	lung inflammation	J:79254
	microcytic anemia	J:79254
	oxidative stress	J:79254
	poor grooming	J:79254
	postnatal lethality, incomplete penetrance	J:79254
	premature death	J:79254
	proximal convoluted tubule brush border loss	J:62437
	renal cast	J:62437
	renal tubular necrosis	J:62437
	small testis	J:79254
	spleen hyperplasia	J:79254
Hmox1tm1Ysh/Hmox1+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal cardiac muscle contractility	J:95461
	abnormal cardiovascular system physiology	J:95461
	increased myocardial infarct size	J:95461
	myocardium necrosis	J:95461
Hmox1tm1Ysh/Hmox1tm1Ysh involves: 129S1/Sv * 129X1/SvJ * C57BL/6	prenatal lethality, complete penetrance	J:95461